MeDIP assay. DRGFP U2OS cells were treated with 0.5 M Shield1 and 0.2 mM TA for 2 h. * p < 0.05, ** p < 0.01. ns: non-significant. For -1500 to 1000 locus, Sce-I+ vs D-2-HG, D-2-HG vs D-2-HG + alphaKG, all p < 0.0001; -1500, D-2-HG vs D-2-HG + TET1/TET2, p < 0.0001; -500, D-2-HG vs D-2-HG + TET1, p = 0.0423; D-2-HG vs D-2-HG + TET2, p = 0.0230; -180, D-2-HG vs D-2-HG + TET1, p = 0.0014; D-2-HG vs D-2-HG + TET2, p = 0.0006; 150, D-2-HG vs D-2-HG + TET1, p = 0.0010; D-2-HG vs D-2-HG + TET2, p = 0.0034; 500, D-2-HG vs D-2-HG + TET1, p = 0.0060; D-2-HG vs D-2-HG + TET2, p = 0.0156; 1000, D-2-HG vs D-2-HG + TET1, p = 0.0024; D-2-HG vs D-2-HG + TET2, p = 0.0096; group differences were tested with one-way ANOVA. Data are mean SEM from three independent experiments.
